1. Chan, K.S., Lai, S.T., Chu, C.M., Tsui, E., Tarn, C.Y., Wong, M.M., Tse, M. W., Que, T.L., Peiris, J.S., Sung, J., et al. (2003). Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 9, 399–406.
2. Chen, Y., Guo, J.J., Healy, D.P., and Zhan, S. (2007). Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: A meta-analysis. Pharmacy pract (Granada Ed impr) 5, 1–9.
3. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet 395, 497–506.
4. Maxmen, A. (2020). More than 80 clinical trials launch to test Coronavirus treatments. Nature 578, 347–348.
5. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., and Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel Coronavirus (2019-nCoV) in vitro. Cell Res doi: https://doi.org/10.1038/s41422-020-0282-0.